US20100310668A1 - Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide - Google Patents
Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Download PDFInfo
- Publication number
- US20100310668A1 US20100310668A1 US12/867,326 US86732609A US2010310668A1 US 20100310668 A1 US20100310668 A1 US 20100310668A1 US 86732609 A US86732609 A US 86732609A US 2010310668 A1 US2010310668 A1 US 2010310668A1
- Authority
- US
- United States
- Prior art keywords
- active pharmaceutical
- pharmaceutical ingredient
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 49
- -1 5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene Chemical group 0.000 title description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 92
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- WINHZLLDWRZWRT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(C=C2C3=CC(F)=CC=C3NC2=O)=C1C WINHZLLDWRZWRT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 47
- 239000002245 particle Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 30
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 30
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 26
- 239000008188 pellet Substances 0.000 claims description 25
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 10
- 239000000155 melt Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 239000002775 capsule Substances 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 229940049920 malate Drugs 0.000 description 13
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 13
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 9
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 9
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 238000005280 amorphization Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 6
- 229940034785 sutent Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000905 isomalt Substances 0.000 description 5
- 235000010439 isomalt Nutrition 0.000 description 5
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003085 Kollidon® CL Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000004701 malic acid derivatives Chemical class 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide and a process of preparing such composition.
- the compound N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (herein also referred to as compound I) is a receptor tyrosine kinase inhibitor which is used to treat disorders like renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Its activity relies on the inhibition of cellular signaling by targeting multiple receptor tyrosine kinases including platelet-derived growth factor receptors and vascular endothelial growth factor receptors. Since both kinds of receptors are involved in tumor angiogenesis and tumor cell proliferation, the simultaneous inhibition of these targets results in both reduced tumor vascularization and cancer cell death. These effects are responsible for the finally observed shrinkage of the renal cell carcinoma and gastrointestinal stromal tumor, respectively.
- WO 01/060814 discloses two processes of preparing compound I. According to these and other known manufacturing processes, compound I is obtained as a solid. One of the forms of compound I is its crystalline malic acid salt as described in WO 03/016305. The solid exhibits poor solubility in water affecting its oral bioavailability. Moreover, it has been reported that it causes manufacturing problems when being processed by higher concentrations, especially concentrations over 40 wt. % (see for example WO 04/024127).
- compound I is administered in a dose of 50 mg once daily, which, if necessary, has to be varied according to individual tolerance and safety.
- individual dosage forms generally contain 12.5, 25 and 50 mg of compound I.
- Capsules comprising the malate salt of compound I are sold under the brand name Sutent® (by Pfizer Pharma).
- composition comprising compound I or a pharmaceutically acceptable salt thereof which does not encounter the above problems.
- composition should possess improved properties like solubility, homogeneity and flowability.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising N-[2-(di-ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is present in amorphous or partially amorphous form.
- amorphous form refers to a form of active pharmaceutical ingredient which has no long-range order like crystalline forms.
- the atoms of a material present in amorphous form exist in a non-uniform array. It is for example possible to distinguish amorphous from crystalline forms of a compound by powder X-ray diffraction.
- active pharmaceutical ingredient refers to compound I in its salt free or salt form.
- active pharmaceutical ingredient refers to compound I including the salt component.
- partially amorphous form refers to a form of the active pharmaceutical ingredient comprising aside from a portion of it in amorphous form a portion in crystalline form.
- at least 10 wt. %, more preferably at least 20 wt. %, at least 30 wt. %, at least 40 wt. %, at least 50 wt. % of the active pharmaceutical ingredient are in amorphous form, even more preferably at least 90 wt. %, most preferably at least 98 wt. %, wherein the respective amounts being referred to the total weight of the active pharmaceutical ingredient in the composition of the present invention.
- pharmaceutical composition refers to single dosage forms, such as tablets, capsules, pellets, etc., as well as powders or granules which are used in the preparation of single dosage forms. Where it is referred to the total weight of the pharmaceutical composition and the pharmaceutical composition in a single dosage form the total weight is the weight of the single dosage form excluding, if applicable, the weight of any coating or capsule shell.
- the active pharmaceutical ingredient in the pharmaceutical composition of the present invention is present in spray dried form or lyophilized form.
- the pharmaceutical composition of the present invention has a mean particle size of 0.3 to 300 ⁇ m, preferably 5 to 300 ⁇ m.
- a bulk density of the pharmaceutical composition of the first embodiment ranging from of 0.2 to 0.8 g/ml, preferably of 0.25 to 0.7 g/ml, more preferably of 0.3 to 0.6 g/ml is advantageous.
- the pharmaceutical composition of the first embodiment of the invention preferably possesses Hausner ratios in the range of 1.1 to 1.6, preferably of 1.2 to 1.5.
- the Hausner factor is the ratio of bulk density to tapped density.
- the composition is obtainable by spray drying the active pharmaceutical ingredient in the presence of at least one of the following excipients: polymers based on cellulose, polyvinylpyrrolidone (PVP) or vinylpyrrolidone-vinyl acetate copolymers. More preferably, a combination of at least one insoluble and at least one soluble excipient is used.
- soluble and insoluble refers to the solubility of the excipient in the solvent used in the spray drying step.
- PVP also serves as crystallization inhibitor and thus stabilizes the amorphous or partially amorphous form into which compound I passes during the spray-drying process.
- crystallization inhibitors are e.g. organic acids, e.g. citric acid; inorganic salts, e.g. ammonium carbonate; and methacrylates, preferably methacrylates with low glass transition temperatures.
- one or more excipients can be present.
- mixtures of soluble and insoluble excipients are employed as explained in more detail below with respect to the process of the invention.
- the active pharmaceutical ingredient in the pharmaceutical composition of the present invention is a) layered onto particles or pellets comprising one or more pharmaceutically acceptable excipients, or b) coated with one or more pharmaceutically acceptable excipients, or c) dispersed or dissolved in a solid melt comprising one or more pharmaceutically acceptable excipients.
- the pharmaceutical composition of the present invention has a mean particle size of 1 to 1500 ⁇ m, preferably 3 to 500 ⁇ m.
- a bulk density of the pharmaceutical composition of the second embodiment ranging from of 0.3 to 0.85 g/ml, preferably of 0.4 to 0.8 g/ml, more preferably of 0.4 to 0.7 g/ml is advantageous.
- the pharmaceutical composition of the second embodiment of the invention preferably possesses Hausner ratios in the range of 1.05 to 1.45, preferably of 1.1 to 1.4.
- the Hausner factor is the ratio of bulk density to tapped density.
- the composition can be obtained for example by dispersing the particles or pellets in a solvent wherein they are non-soluble, dissolving the active pharmaceutical ingredient in this dispersion and removing the solvent.
- the particles or pellets can be dispersed in a solution of the active pharmaceutical ingredient in a suitable solvent before removal of the solvent.
- the particles or pellets may be sprayed with a solution of the active pharmaceutical ingredient and subsequently dried.
- the composition wherein the active pharmaceutical ingredient is layered onto particles or pellets is obtainable by spraying the particles or pellets with a solution of the active pharmaceutical ingredient in a fluid bed dryer.
- any suitable solvent may be employed.
- water or ethanol are suitable solvents, preferably water.
- the active pharmaceutical ingredient may be layered onto the particles or pellets together with at least one further pharmaceutically acceptable excipient, such as a binder.
- suitable excipients are, for example, sugar, alcohols, polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), and dextrines.
- any suitable particle or pellet can be used, such as commercially available inert pellets or granules.
- the particles or pellets can, for example, be prepared by granulation, such as wet granulation of a mixture of a soluble and an insoluble excipient, such as mannitol and microcrystalline cellulose. Single substances can also be utilized.
- the pharmaceutical composition of the present invention comprises the active pharmaceutical ingredient b) coated with one or more pharmaceutical excipients
- any suitable excipient for coating the active pharmaceutical ingredient may be employed.
- Suitable excipients are, for example, hydroxypropylmethyl cellulose (HPMC) and polyvinylpyrrolidone (PVP).
- HPMC hydroxypropylmethyl cellulose
- PVP polyvinylpyrrolidone
- the coating of the active pharmaceutical ingredient with the excipient can be conducted by any process known to a person skilled in the art.
- the active pharmaceutical ingredient can be dispersed in a solvent in which it is not soluble and the excipient can be dissolved in this dispersion before removal of the solvent.
- the active pharmaceutical ingredient can be dispersed in a solution of the excipient in a suitable solvent before removal of the solvent.
- a solution of the excipient may be sprayed onto particles of the active pharmaceutical ingredient, for example in a fluid bed dryer.
- the active pharmaceutical ingredient can be c) dispersed or dissolved in a melt of one or more pharmaceutically acceptable excipients.
- the melt is solidified, for example, by cooling, the active pharmaceutical ingredient is molecularly dispersed within the excipient(s) or converted into its amorphous or at least partially amorphous state.
- Any excipient suitable for the preparation of such melts can be employed. Suitable excipients for this embodiment are, for example, polyethylene glycols (PEGs), polyvinylpyrrolidone (PVP), polyvinylacetat (PVA), cellulose derivatives, sugar alcohols, methacrylates and mixtures of mono-, di- and triglycerides. Also mixtures of one or more of these excipients can be used.
- composition of the present invention are explained below in the description of the processes for the preparation of the composition.
- the active pharmaceutical ingredient is preferably present in the pharmaceutical composition in an amount of more than 40 wt. %, more preferably at least 53 wt. % and even more preferably at least 70 wt. %, wherein the respective amounts being referred to the weight of the total composition. Further preferred portions of the active pharmaceutical ingredient in the pharmaceutical composition are more than 40 wt. %, more than 41 wt. %, more than 42 wt. %, more than 43 wt. %, more than 44 wt. %, more than 45 wt. %, more than 50 wt. %, more than 53 wt. %, more than 60 wt. % or more than 70 wt. %, wherein the respective amounts are being referred to the weight of the total composition.
- the pharmaceutical composition of the present invention Due to the amorphous form of the active pharmaceutical ingredient, the pharmaceutical composition of the present invention possesses excellent solubility, homogeneity and flowability. Further, it shows a great workability even if the portion of active pharmaceutical ingredient in the composition is higher than 40 wt. %.
- the pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable excipients, such as fillers, binding agents, lubricants, glidants, antisticking agents, crystallization inhibitors and disintegrating agents.
- pharmaceutically acceptable excipients conventional excipients known to the person skilled in the art may be used. See for example “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende füre”, edited by H. P. Fiedler, 4th Edition, Edito Cantor, Aulendorf and earlier editions, and “Handbook of Pharmaceutical Excipients”, Third Edition, edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press, London.
- the fillers are lactose, mannitol, sorbitol or microcrystalline cellulose.
- the filler is suitably present in an amount of 0 to 80 wt. %, preferably of 10 to 20 wt. % of the total weight of the composition.
- the binding agent can for example be microcrystalline cellulose (MCC) or hydroxypropylmethyl cellulose (HPMC).
- MCC microcrystalline cellulose
- HPMC hydroxypropylmethyl cellulose
- the binding agent is present in an amount of 1 to 25 wt. %, more preferably at 2 to 10 wt. % of the total weight of the composition.
- the lubricant is preferably a stearate, more preferably an earth alkali metal stearate, such as magnesium stearate.
- the lubricant is suitably present in an amount of 0.1 to 2 wt. %, preferably about 1 wt. % of the total weight of the composition.
- Preferred crystallization inhibitors may be selected from the group consisting of polyvinylpyrrolidone (PVP); organic acids, e.g. citric acid; inorganic salts, e.g. ammonium carbonate; and methacrylates.
- PVP polyvinylpyrrolidone
- organic acids e.g. citric acid
- inorganic salts e.g. ammonium carbonate
- methacrylates e.g., a crystallization inhibitor.
- the crystallization inhibitor is suitably present in an amount of 0.1 to 10 wt. %, preferably 2 to 5 wt. % of the total weight of the composition.
- Preferred disintegrating agents are croscarmellose sodium, sodium carboxymethyl starch or cross-linked polyvinylpyrrolidone (crospovidone).
- the disintegrating agent is suitably present in an amount of 0.1 to 20 wt. %, more preferably at about 0.5 to 7 wt. % of the total weight of the composition.
- the glidant can for example be colloidal silicon dioxide.
- the binding agent is present in an amount of 0.5 to 8 wt. %, more preferably at 0.5 to 3 wt. % of the total weight of the composition.
- the antisticking agent is for example talcum and may be present in amounts of 1 to 5%.wt, more preferably in an amount of 1.5 to 3 wt. % of the total weight of the composition.
- the pharmaceutical composition of the present invention can be formulated in any known matter, preferably as tablets, capsules, granules, pellets or sachets.
- a particularly preferred pharmaceutical composition is in the form of capsules.
- the pharmaceutical composition may contain dosage amounts of 12.5, 25 and 50 mg of the active pharmaceutical ingredient.
- the administered amount can be readily varied according to individual tolerance and safety warranting more flexible dosing than the standard dose of 50 mg once daily.
- a further aspect of the present invention provides a process of preparing a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient wherein the active pharmaceutical ingredient is present in amorphous or partially amorphous form.
- the process comprises the following steps:
- the active pharmaceutical ingredient is transferred in step (b) into its amorphous or partially amorphous form by spray drying in the presence or absence of any excipient(s).
- step (b) the active pharmaceutical ingredient is transferred in step (b) into its amorphous or partially amorphous form by spray drying in the presence or absence of any excipient(s).
- Preferred excipients have been exemplified above with respect to the spray dried product.
- mean particle sizes of 5 to 300 ⁇ m and bulk densities of 0.3 to 0.7 g/ml are preferably obtained.
- the ratio between tapped density and bulk density is strongly dependent on the choice of excipients, and preferred granulates according to this embodiment of the present invention have Hausner ratios between 1.2 and 1.5.
- the active pharmaceutical ingredient is transferred into its amorphous or partially amorphous form in above step (b) by lyophilizing, i.e. the solvent is evaporated from a solution containing the active pharmaceutical ingredient and optionally one or more excipients via freeze-drying under vacuum.
- lyophilizing i.e. the solvent is evaporated from a solution containing the active pharmaceutical ingredient and optionally one or more excipients via freeze-drying under vacuum.
- soluble and insoluble excipients are employed.
- soluble and insoluble refers to the solubility of the excipient in the solvent used in the lyophilizing step.
- Application of this embodiment results in an amorphization or partial amorphization of the active pharmaceutical ingredient.
- the drying parameters and, if applicable, the milling technology mean particle sizes of 0.3 to 300 ⁇ m and bulk densities between 0.25 and 0.6 g/ml are preferably obtained.
- Preferred granulates according to this embodiment of the present invention have Hausner ratios between 1.2 and 1.5.
- the active pharmaceutical ingredient is transferred into its amorphous or partially amorphous form by a) layering the active pharmaceutical ingredient onto particles or pellets comprising one or more pharmaceutically acceptable excipients or by b) coating the active pharmaceutical ingredient with one or more pharmaceutically acceptable excipients or by c) dispersing or dissolving the active pharmaceutical ingredient in a melt comprising one or more pharmaceutically acceptable excipients.
- the active pharmaceutical ingredient is layered onto particles or pellets comprising one or more excipients, leading to amorphization or partial amorphization of the active pharmaceutical ingredient.
- a mixture of a soluble and an insoluble excipient such as mannitol and microcrystalline cellulose is used.
- Single substances can also be utilized.
- the particles or pellets can, for example, be sprayed with an aqueous solution of the active pharmaceutical ingredient additionally containing one or more of the following excipients: sugar alcohols, PVP, HPMC and dextrins.
- excipients sugar alcohols, PVP, HPMC and dextrins.
- mean particle sizes of 20 to 1500 ⁇ m and bulk densities of 0.5 to 0.85 g/ml can be obtained.
- the granulates according to this embodiment of the present invention can have Hausner ratios between 1.05 and 1.35.
- the active pharmaceutical ingredient is coated with one or more excipients such as HPMC or PVP that enhance the solubility of the active pharmaceutical ingredient.
- This coating process leads to an at least partial amorphization of the active pharmaceutical ingredient.
- particle sizes of 3 to 500 ⁇ m and bulk densities between 0.3 to 0.8 g/ml can be obtained.
- the granulates according to this embodiment of the present invention can have Hausner ratios between 1.1 and 1.45.
- the active pharmaceutical ingredient is dispersed or dissolved in a melt of one or more excipients.
- the active pharmaceutical ingredient is molecularly dispersed within the excipient(s) or passes into an amorphous or partially amorphous state.
- excipients such as polyethylene glycols (PEGs), PVP, polyvinyl acetate (PVA), cellulose derivatives, sugar alcohols, methacrylates and mixtures of mono-, di- and triglycerides are employed.
- mean particle sizes of 1 to 500 ⁇ m and bulk densities of 0.4 to 0.8 g/ml can be obtained.
- Granulates according to this embodiment of the present invention can have Hausner ratios between 1.05 and 1.4.
- FIG. 1 shows the XRPD of compound I malate/isomalt lyophilizate.
- FIG. 2 shows the dissolution profiles of capsules according to the present invention containing compound I malate/isomalt lyophilizate compared to commercial Sutent® sunitinib capsules.
- FIG. 3 shows the XRPD of compound I malate spray dried in the presence of PVP.
- FIG. 4 shown the dissolution profiles of capsules according to the present invention containing compound I malate spray dried in the presence of PVP (BR7A) compared to commercial Sutent® sunitinib capsules.
- Compound I and mannitol were lyophilized from an aqueous-alcoholic solution (pH 7.4) at 20 to 100 mbar and ⁇ 40 to ⁇ 60° C. and dried at 1013 mbar and 25 to 45° C.
- the lyophilizate was mixed with sodium croscarmellose and magnesium stearate and filled into hard gelatin capsules (size 4).
- Microcrystalline cellulose was suspended in an aqueous solution of compound I and povidone (5 to 50% combined dry weight). This suspension was spray dried. Then, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate were added and mixed with the granules obtained in the spray drying process. The mixture was filled into hard gelatin capsules (size 4).
- API particles (mean particle size 0.4 to 400 ⁇ m) are sprayed with an aqueous solution of to 20% of HPMC in a fluid bed dryer (nozzle width 0.8 to 1.2 mm, inlet temperature 50 to 70° C., product temperature about 40° C.) and afterwards dried for up to 1.5 hours at 30 to 50° C. Lactose and sodium croscarmellose are mixed with the coated granules. Finally, magnesium stearate is added. The mixture is filled into hard gelatine capsules (size 4).
- Ingredient Product Function 25 mg dosage Compound I API 25 MCC Anvicel filler 12.8 PH101 PVP Kollidon 25 binder 5.0 Sodium croscarmellose Ac-Di-SOL disintegrant 3.0 Colloidal silicon dioxide Aerosil glidant 0.2 Magnesium stearate tbd antisticking 0.6 Total 46.6
- MCC 0.1 mg colloidal silicon dioxide and 0.3 mg magnesium stearate are fluid bed granulated with a suspension of API and PVP in water (5 to 50%). The resulting granules are sieved (mesh width 0.5 to 1.2 mm). Then, sodium croscarmellose and the residual colloidal silicon dioxide and magnesium stearate are added and mixed with the granules. The mixture is filled into hard gelatine capsules (size 4).
- pellets are sprayed with an aqueous solution of API, HPMC and talcum at a temperature of 30 to 50° C. Afterwards, the pellets are dried for up to 1.5 hours at 30 to 45° C. The coated pellets are filled into hard gelatine capsules (size 4).
- Ingredient Product Function 25 mg dosage Compound I API 25 Sorbitol Neosorb filler 18.4 Crospovidone Kollidon CL disintegrant 2.5 Colloidal silicon dioxide Aerosil glidant 0.2 Magnesium stearate tbd antisticking 0.5 Total 46.6
- API and sorbitol are melt extruded in a twice screw extruder at 110 to 180° C.
- the extrudat is sieved (mesh width 0.5 to 1.2 mm) or spheronized and mixed with crospovidone, colloidal silicon dioxide and magnesium stearate.
- the mixture is filled into hard gelatine capsules (size 4).
- the XRPD of the compound I malate/isomalt lyophilizate is shown in FIG. 1 .
- the XRPD demonstrates that the lyophilizate contains compound I malate substantially in amorphous form.
- the dissolution profile of the pharmaceutical composition obtained in this example was measured and compared with the dissolution profile of commercial Sutent® 12.5 mg sunitib capsules.
- the dissolution profiles were measured in 900 ml of phosphate buffer pH 3.2 using a spiral capsule sinker at 37° C. and 50 rpm paddle (app. II).
- the dissolution profiles are shown in FIG. 2 which demonstrates that the capsules of the present invention dissolve even faster than the commercial sunitib capsules.
- the XRPD of the spray dried product is shown in FIG. 3 .
- the XRPD demonstrates that compound I malate is present in amorphous form.
- the dissolution profile of the capsules obtained in this example was compared with the dissolution profile of commercial Sutent® 12.5 mg sunitinib capsules.
- the dissolution profiles were measured in 900 ml of phosphate puffer pH 3.2 using a spiral capsule sinker at 37° C. and 50 rpm paddle (app.II).
- the dissolution profiles are shown in FIG. 4 which demonstrates that the dissolution of the capsules of the present invention is even faster then the dissolution of the commercial sutent capsules.
Abstract
The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient.
Description
- The invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide and a process of preparing such composition.
- The compound N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (herein also referred to as compound I) is a receptor tyrosine kinase inhibitor which is used to treat disorders like renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Its activity relies on the inhibition of cellular signaling by targeting multiple receptor tyrosine kinases including platelet-derived growth factor receptors and vascular endothelial growth factor receptors. Since both kinds of receptors are involved in tumor angiogenesis and tumor cell proliferation, the simultaneous inhibition of these targets results in both reduced tumor vascularization and cancer cell death. These effects are responsible for the finally observed shrinkage of the renal cell carcinoma and gastrointestinal stromal tumor, respectively.
- Compound I and its pharmaceutical effects on disorders like cancer are described in WO 01/060814. Further medical uses of compound I and its salts are inter alia known from WO 01/045689 and WO 03/035009.
- WO 01/060814 discloses two processes of preparing compound I. According to these and other known manufacturing processes, compound I is obtained as a solid. One of the forms of compound I is its crystalline malic acid salt as described in WO 03/016305. The solid exhibits poor solubility in water affecting its oral bioavailability. Moreover, it has been reported that it causes manufacturing problems when being processed by higher concentrations, especially concentrations over 40 wt. % (see for example WO 04/024127).
- Typically, compound I is administered in a dose of 50 mg once daily, which, if necessary, has to be varied according to individual tolerance and safety. Thus, in order to obtain sufficiently flexible dosing, individual dosage forms generally contain 12.5, 25 and 50 mg of compound I. Capsules comprising the malate salt of compound I are sold under the brand name Sutent® (by Pfizer Pharma).
- The above-mentioned manufacturing problems can attribute to the crystalline form of compound I. Moreover, good homogeneity and flowability of a pharmaceutical composition are a prerequisite for a successful manufacture of for example tablets and capsules on a production scale.
- It is therefore an object of the invention to provide a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof which does not encounter the above problems. In particular the composition should possess improved properties like solubility, homogeneity and flowability.
- It has now been found that the above problems can be overcome by providing a pharmaceutical composition comprising compound I or a salt of it in amorphous form.
- Thus, the present invention relates to a pharmaceutical composition comprising N-[2-(di-ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is present in amorphous or partially amorphous form.
- N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound I) has the following chemical structure:
- Compound I as well as its salts can be readily synthesized using techniques well known in the art. Syntheses of compound I are disclosed for example in WO 01/060814.
- The term “amorphous form” refers to a form of active pharmaceutical ingredient which has no long-range order like crystalline forms. The atoms of a material present in amorphous form exist in a non-uniform array. It is for example possible to distinguish amorphous from crystalline forms of a compound by powder X-ray diffraction.
- The term “active pharmaceutical ingredient” (API) refers to compound I in its salt free or salt form. Thus, if a pharmaceutically acceptable salt of compound I is employed, active pharmaceutical ingredient refers to compound I including the salt component.
- The term “partially amorphous form” refers to a form of the active pharmaceutical ingredient comprising aside from a portion of it in amorphous form a portion in crystalline form. Preferably, at least 10 wt. %, more preferably at least 20 wt. %, at least 30 wt. %, at least 40 wt. %, at least 50 wt. % of the active pharmaceutical ingredient are in amorphous form, even more preferably at least 90 wt. %, most preferably at least 98 wt. %, wherein the respective amounts being referred to the total weight of the active pharmaceutical ingredient in the composition of the present invention.
- The term “pharmaceutical composition” refers to single dosage forms, such as tablets, capsules, pellets, etc., as well as powders or granules which are used in the preparation of single dosage forms. Where it is referred to the total weight of the pharmaceutical composition and the pharmaceutical composition in a single dosage form the total weight is the weight of the single dosage form excluding, if applicable, the weight of any coating or capsule shell.
- In a first embodiment the active pharmaceutical ingredient in the pharmaceutical composition of the present invention is present in spray dried form or lyophilized form.
- In this first embodiment advantageous properties regarding solubility, homogeneity and flowability can be achieved if the pharmaceutical composition of the present invention has a mean particle size of 0.3 to 300 μm, preferably 5 to 300 μm.
- A bulk density of the pharmaceutical composition of the first embodiment ranging from of 0.2 to 0.8 g/ml, preferably of 0.25 to 0.7 g/ml, more preferably of 0.3 to 0.6 g/ml is advantageous.
- The pharmaceutical composition of the first embodiment of the invention preferably possesses Hausner ratios in the range of 1.1 to 1.6, preferably of 1.2 to 1.5. The Hausner factor is the ratio of bulk density to tapped density.
- If the active pharmaceutical ingredient is present in spray dried form, preferably the composition is obtainable by spray drying the active pharmaceutical ingredient in the presence of at least one of the following excipients: polymers based on cellulose, polyvinylpyrrolidone (PVP) or vinylpyrrolidone-vinyl acetate copolymers. More preferably, a combination of at least one insoluble and at least one soluble excipient is used. Here, “soluble” and “insoluble” refers to the solubility of the excipient in the solvent used in the spray drying step.
- In this context PVP also serves as crystallization inhibitor and thus stabilizes the amorphous or partially amorphous form into which compound I passes during the spray-drying process. Other possible crystallization inhibitors are e.g. organic acids, e.g. citric acid; inorganic salts, e.g. ammonium carbonate; and methacrylates, preferably methacrylates with low glass transition temperatures.
- If the active pharmaceutical ingredient is present in lyophilized form, one or more excipients can be present. Preferably, mixtures of soluble and insoluble excipients are employed as explained in more detail below with respect to the process of the invention.
- In a second embodiment the active pharmaceutical ingredient in the pharmaceutical composition of the present invention is a) layered onto particles or pellets comprising one or more pharmaceutically acceptable excipients, or b) coated with one or more pharmaceutically acceptable excipients, or c) dispersed or dissolved in a solid melt comprising one or more pharmaceutically acceptable excipients.
- In this second embodiment advantageous properties regarding solubility, homogeneity and flowability can be achieved if the pharmaceutical composition of the present invention has a mean particle size of 1 to 1500 μm, preferably 3 to 500 μm.
- A bulk density of the pharmaceutical composition of the second embodiment ranging from of 0.3 to 0.85 g/ml, preferably of 0.4 to 0.8 g/ml, more preferably of 0.4 to 0.7 g/ml is advantageous.
- The pharmaceutical composition of the second embodiment of the invention preferably possesses Hausner ratios in the range of 1.05 to 1.45, preferably of 1.1 to 1.4. The Hausner factor is the ratio of bulk density to tapped density.
- If the active pharmaceutical ingredient is a) layered onto particles or pellets, the composition can be obtained for example by dispersing the particles or pellets in a solvent wherein they are non-soluble, dissolving the active pharmaceutical ingredient in this dispersion and removing the solvent. Alternatively, the particles or pellets can be dispersed in a solution of the active pharmaceutical ingredient in a suitable solvent before removal of the solvent. In a further alternative embodiment the particles or pellets may be sprayed with a solution of the active pharmaceutical ingredient and subsequently dried. Preferably, the composition wherein the active pharmaceutical ingredient is layered onto particles or pellets is obtainable by spraying the particles or pellets with a solution of the active pharmaceutical ingredient in a fluid bed dryer.
- As a solvent any suitable solvent may be employed. For example, water or ethanol are suitable solvents, preferably water.
- In a further embodiment the active pharmaceutical ingredient may be layered onto the particles or pellets together with at least one further pharmaceutically acceptable excipient, such as a binder. Suitable excipients are, for example, sugar, alcohols, polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), and dextrines.
- As the particles or pellets any suitable particle or pellet can be used, such as commercially available inert pellets or granules. Alternatively, the particles or pellets can, for example, be prepared by granulation, such as wet granulation of a mixture of a soluble and an insoluble excipient, such as mannitol and microcrystalline cellulose. Single substances can also be utilized.
- Where the pharmaceutical composition of the present invention comprises the active pharmaceutical ingredient b) coated with one or more pharmaceutical excipients, any suitable excipient for coating the active pharmaceutical ingredient may be employed. Suitable excipients are, for example, hydroxypropylmethyl cellulose (HPMC) and polyvinylpyrrolidone (PVP). The coating process results in an at least partial amorphization of the active pharmaceutical ingredient, thereby enhancing its solubility.
- The coating of the active pharmaceutical ingredient with the excipient can be conducted by any process known to a person skilled in the art. For example, the active pharmaceutical ingredient can be dispersed in a solvent in which it is not soluble and the excipient can be dissolved in this dispersion before removal of the solvent. Alternatively, the active pharmaceutical ingredient can be dispersed in a solution of the excipient in a suitable solvent before removal of the solvent. In a further embodiment a solution of the excipient may be sprayed onto particles of the active pharmaceutical ingredient, for example in a fluid bed dryer.
- The active pharmaceutical ingredient can be c) dispersed or dissolved in a melt of one or more pharmaceutically acceptable excipients. When the melt is solidified, for example, by cooling, the active pharmaceutical ingredient is molecularly dispersed within the excipient(s) or converted into its amorphous or at least partially amorphous state. Any excipient suitable for the preparation of such melts can be employed. Suitable excipients for this embodiment are, for example, polyethylene glycols (PEGs), polyvinylpyrrolidone (PVP), polyvinylacetat (PVA), cellulose derivatives, sugar alcohols, methacrylates and mixtures of mono-, di- and triglycerides. Also mixtures of one or more of these excipients can be used.
- Further preferred embodiments of the composition of the present invention are explained below in the description of the processes for the preparation of the composition.
- The active pharmaceutical ingredient is preferably present in the pharmaceutical composition in an amount of more than 40 wt. %, more preferably at least 53 wt. % and even more preferably at least 70 wt. %, wherein the respective amounts being referred to the weight of the total composition. Further preferred portions of the active pharmaceutical ingredient in the pharmaceutical composition are more than 40 wt. %, more than 41 wt. %, more than 42 wt. %, more than 43 wt. %, more than 44 wt. %, more than 45 wt. %, more than 50 wt. %, more than 53 wt. %, more than 60 wt. % or more than 70 wt. %, wherein the respective amounts are being referred to the weight of the total composition.
- Due to the amorphous form of the active pharmaceutical ingredient, the pharmaceutical composition of the present invention possesses excellent solubility, homogeneity and flowability. Further, it shows a great workability even if the portion of active pharmaceutical ingredient in the composition is higher than 40 wt. %.
- The pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable excipients, such as fillers, binding agents, lubricants, glidants, antisticking agents, crystallization inhibitors and disintegrating agents. As pharmaceutically acceptable excipients conventional excipients known to the person skilled in the art may be used. See for example “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete”, edited by H. P. Fiedler, 4th Edition, Edito Cantor, Aulendorf and earlier editions, and “Handbook of Pharmaceutical Excipients”, Third Edition, edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press, London.
- Preferred examples of the fillers are lactose, mannitol, sorbitol or microcrystalline cellulose. The filler is suitably present in an amount of 0 to 80 wt. %, preferably of 10 to 20 wt. % of the total weight of the composition.
- The binding agent can for example be microcrystalline cellulose (MCC) or hydroxypropylmethyl cellulose (HPMC). Preferably the binding agent is present in an amount of 1 to 25 wt. %, more preferably at 2 to 10 wt. % of the total weight of the composition.
- The lubricant is preferably a stearate, more preferably an earth alkali metal stearate, such as magnesium stearate. The lubricant is suitably present in an amount of 0.1 to 2 wt. %, preferably about 1 wt. % of the total weight of the composition.
- Preferred crystallization inhibitors may be selected from the group consisting of polyvinylpyrrolidone (PVP); organic acids, e.g. citric acid; inorganic salts, e.g. ammonium carbonate; and methacrylates. The crystallization inhibitor is suitably present in an amount of 0.1 to 10 wt. %, preferably 2 to 5 wt. % of the total weight of the composition.
- Preferred disintegrating agents are croscarmellose sodium, sodium carboxymethyl starch or cross-linked polyvinylpyrrolidone (crospovidone). The disintegrating agent is suitably present in an amount of 0.1 to 20 wt. %, more preferably at about 0.5 to 7 wt. % of the total weight of the composition.
- The glidant can for example be colloidal silicon dioxide. Preferably the binding agent is present in an amount of 0.5 to 8 wt. %, more preferably at 0.5 to 3 wt. % of the total weight of the composition.
- The antisticking agent is for example talcum and may be present in amounts of 1 to 5%.wt, more preferably in an amount of 1.5 to 3 wt. % of the total weight of the composition.
- A person skilled in the art may use these or other excipients in regard to the selected process of preparing the pharmaceutical composition of the invention.
- The pharmaceutical composition of the present invention can be formulated in any known matter, preferably as tablets, capsules, granules, pellets or sachets. A particularly preferred pharmaceutical composition is in the form of capsules. The pharmaceutical composition may contain dosage amounts of 12.5, 25 and 50 mg of the active pharmaceutical ingredient. Thus the administered amount can be readily varied according to individual tolerance and safety warranting more flexible dosing than the standard dose of 50 mg once daily.
- A further aspect of the present invention provides a process of preparing a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient wherein the active pharmaceutical ingredient is present in amorphous or partially amorphous form. The process comprises the following steps:
- (a) providing compound I or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient and optionally at least one pharmaceutically acceptable excipient; and
(b) transferring the active pharmaceutical ingredient into its amorphous or partially amorphous form. - In a first embodiment of this process the active pharmaceutical ingredient is transferred in step (b) into its amorphous or partially amorphous form by spray drying in the presence or absence of any excipient(s). This leads to an enhanced particle surface porosity and, if at least one excipient is present, an optimized embedding of the active pharmaceutical ingredient into the excipient(s), thereby improving solubility, homogeneity and flowability of the composition of the invention.
- Preferred excipients have been exemplified above with respect to the spray dried product.
- Depending on the excipients and the process parameters, mean particle sizes of 5 to 300 μm and bulk densities of 0.3 to 0.7 g/ml are preferably obtained. The ratio between tapped density and bulk density is strongly dependent on the choice of excipients, and preferred granulates according to this embodiment of the present invention have Hausner ratios between 1.2 and 1.5.
- In a second embodiment of the process of the invention, the active pharmaceutical ingredient is transferred into its amorphous or partially amorphous form in above step (b) by lyophilizing, i.e. the solvent is evaporated from a solution containing the active pharmaceutical ingredient and optionally one or more excipients via freeze-drying under vacuum. This leads to an enhanced particle surface porosity and, if at least one excipient is present, an optimized embedding of the active pharmaceutical ingredient into the excipient(s), thereby improving solubility, homogeneity and flowability.
- Preferably, mixtures of soluble and insoluble excipients in any ratio are employed. Here, “soluble” and “insoluble” refers to the solubility of the excipient in the solvent used in the lyophilizing step. Application of this embodiment results in an amorphization or partial amorphization of the active pharmaceutical ingredient. Depending on the excipients, the drying parameters and, if applicable, the milling technology, mean particle sizes of 0.3 to 300 μm and bulk densities between 0.25 and 0.6 g/ml are preferably obtained. Preferred granulates according to this embodiment of the present invention have Hausner ratios between 1.2 and 1.5.
- In a third embodiment of the process of the invention, the active pharmaceutical ingredient is transferred into its amorphous or partially amorphous form by a) layering the active pharmaceutical ingredient onto particles or pellets comprising one or more pharmaceutically acceptable excipients or by b) coating the active pharmaceutical ingredient with one or more pharmaceutically acceptable excipients or by c) dispersing or dissolving the active pharmaceutical ingredient in a melt comprising one or more pharmaceutically acceptable excipients.
- In option a) of this process the active pharmaceutical ingredient is layered onto particles or pellets comprising one or more excipients, leading to amorphization or partial amorphization of the active pharmaceutical ingredient.
- Preferably, for the formation of said particles or pellets a mixture of a soluble and an insoluble excipient such as mannitol and microcrystalline cellulose is used. Single substances can also be utilized.
- The particles or pellets can, for example, be sprayed with an aqueous solution of the active pharmaceutical ingredient additionally containing one or more of the following excipients: sugar alcohols, PVP, HPMC and dextrins. Depending on the excipients and the granulation parameters, mean particle sizes of 20 to 1500 μm and bulk densities of 0.5 to 0.85 g/ml can be obtained. The granulates according to this embodiment of the present invention can have Hausner ratios between 1.05 and 1.35.
- In option b) of the above process the active pharmaceutical ingredient is coated with one or more excipients such as HPMC or PVP that enhance the solubility of the active pharmaceutical ingredient. This coating process leads to an at least partial amorphization of the active pharmaceutical ingredient. Depending on the particle size of the active pharmaceutical ingredient and the process parameters mean particle sizes of 3 to 500 μm and bulk densities between 0.3 to 0.8 g/ml can be obtained. The granulates according to this embodiment of the present invention can have Hausner ratios between 1.1 and 1.45.
- In option c) of the above process the active pharmaceutical ingredient is dispersed or dissolved in a melt of one or more excipients. After the melt has been cooled, the active pharmaceutical ingredient is molecularly dispersed within the excipient(s) or passes into an amorphous or partially amorphous state. Preferably, excipients such as polyethylene glycols (PEGs), PVP, polyvinyl acetate (PVA), cellulose derivatives, sugar alcohols, methacrylates and mixtures of mono-, di- and triglycerides are employed. Depending on the excipients and the milling technology chosen, mean particle sizes of 1 to 500 μm and bulk densities of 0.4 to 0.8 g/ml can be obtained. Granulates according to this embodiment of the present invention can have Hausner ratios between 1.05 and 1.4.
-
FIG. 1 shows the XRPD of compound I malate/isomalt lyophilizate. -
FIG. 2 shows the dissolution profiles of capsules according to the present invention containing compound I malate/isomalt lyophilizate compared to commercial Sutent® sunitinib capsules. -
FIG. 3 shows the XRPD of compound I malate spray dried in the presence of PVP. -
FIG. 4 shown the dissolution profiles of capsules according to the present invention containing compound I malate spray dried in the presence of PVP (BR7A) compared to commercial Sutent® sunitinib capsules. - The invention is now illustrated in the following examples which are not to be constructed as being limiting.
- The following procedure was used to prepare the pharmaceutical composition having the formulation listed in Table 1 and comprising a solid amorphous form of compound I.
- Compound I and mannitol were lyophilized from an aqueous-alcoholic solution (pH 7.4) at 20 to 100 mbar and −40 to −60° C. and dried at 1013 mbar and 25 to 45° C. The lyophilizate was mixed with sodium croscarmellose and magnesium stearate and filled into hard gelatin capsules (size 4).
-
TABLE 1 Ingredient Product Function Amount Compound I micronized API 25 mg Mannitol Mannit filler 18.6 mg Sodium croscarmellose Ac-Di-SOL disintegrant 2.5 mg Magnesium stearate tbd antisticking 0.5 mg Total 46.6 mg - The following procedure was used to prepare the pharmaceutical composition having the formulation listed in Table 2 and comprising a solid amorphous form of compound I.
- Microcrystalline cellulose (MCC) was suspended in an aqueous solution of compound I and povidone (5 to 50% combined dry weight). This suspension was spray dried. Then, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate were added and mixed with the granules obtained in the spray drying process. The mixture was filled into hard gelatin capsules (size 4).
-
TABLE 2 Ingredient Product Function Amount Compound I API 25 mg MCC Avicel PH 101 filler 10.0 mg Povidone Kollidon 25 binder 8.0 mg Sodium croscarmellose Ac-Di-SOL disintegrant 2.8 mg Colloidal silicon dioxide Aerosil glidant 0.2 mg Magnesium stearate tbd antisticking 0.6 mg Total 46.6 mg -
-
Ingredient Product Function 25 mg dosage Compound I API 25 HPMC Klucel Binder 3.0 Lactose Flow lac filler 15.0 Sodium croscarmellose Ac-Di-SOL disintegrant 3.0 Magnesium stearate tbd antisticking 0.6 Total 46.6 - The API particles (mean particle size 0.4 to 400 μm) are sprayed with an aqueous solution of to 20% of HPMC in a fluid bed dryer (nozzle width 0.8 to 1.2 mm,
inlet temperature 50 to 70° C., product temperature about 40° C.) and afterwards dried for up to 1.5 hours at 30 to 50° C. Lactose and sodium croscarmellose are mixed with the coated granules. Finally, magnesium stearate is added. The mixture is filled into hard gelatine capsules (size 4). -
-
Ingredient Product Function 25 mg dosage Compound I API 25 MCC Anvicel filler 12.8 PH101 PVP Kollidon 25 binder 5.0 Sodium croscarmellose Ac-Di-SOL disintegrant 3.0 Colloidal silicon dioxide Aerosil glidant 0.2 Magnesium stearate tbd antisticking 0.6 Total 46.6 - MCC, 0.1 mg colloidal silicon dioxide and 0.3 mg magnesium stearate are fluid bed granulated with a suspension of API and PVP in water (5 to 50%). The resulting granules are sieved (mesh width 0.5 to 1.2 mm). Then, sodium croscarmellose and the residual colloidal silicon dioxide and magnesium stearate are added and mixed with the granules. The mixture is filled into hard gelatine capsules (size 4).
-
-
Ingredient Product Function 25 mg dosage Compound I API 25 Pellets Neutralpellets 50 HPMC Pharmacoat 603 binder 15 Talcum Talcum antisticking 0.3 Total 90.3 - Alternatively, commercially available pellets are sprayed with an aqueous solution of API, HPMC and talcum at a temperature of 30 to 50° C. Afterwards, the pellets are dried for up to 1.5 hours at 30 to 45° C. The coated pellets are filled into hard gelatine capsules (size 4).
-
-
Ingredient Product Function 25 mg dosage Compound I API 25 Sorbitol Neosorb filler 18.4 Crospovidone Kollidon CL disintegrant 2.5 Colloidal silicon dioxide Aerosil glidant 0.2 Magnesium stearate tbd antisticking 0.5 Total 46.6 - API and sorbitol are melt extruded in a twice screw extruder at 110 to 180° C. The extrudat is sieved (mesh width 0.5 to 1.2 mm) or spheronized and mixed with crospovidone, colloidal silicon dioxide and magnesium stearate. The mixture is filled into hard gelatine capsules (size 4).
- The following procedure was used to prepare the pharmaceutical composition having the formulation listed in table 3 and comprising a solid amorphous form of compound I malate.
- 300 mg of compound I malate and 3 g of isomalt were dissolved in 30 ml of water. The solution was lyophilized. The obtained product had a bulk density of 0.31 g/ml. To the lyophilized product were then added microcrystalline cellulose (MCC) and colloidal silicon dioxide. After mixing the ingredients the mixture having a mean particle size of between 16 and 20 μm was filled into hard gelantine capsules (size 2).
-
TABLE 3 Ingredient Product Function Amount Compound I malate API 222.66 mg isomalt lyophilizate MCC Avicel PH 101 filler 10.00 mg Colloidal silicon dioxide Aerosil 200 glidant 1.00 mg Total 233.6 mg - The XRPD of the compound I malate/isomalt lyophilizate is shown in
FIG. 1 . The XRPD demonstrates that the lyophilizate contains compound I malate substantially in amorphous form. - The dissolution profile of the pharmaceutical composition obtained in this example was measured and compared with the dissolution profile of commercial Sutent® 12.5 mg sunitib capsules. The dissolution profiles were measured in 900 ml of phosphate buffer pH 3.2 using a spiral capsule sinker at 37° C. and 50 rpm paddle (app. II). The dissolution profiles are shown in
FIG. 2 which demonstrates that the capsules of the present invention dissolve even faster than the commercial sunitib capsules. - The following procedure was used to prepare the pharmaceutical composition having the formulation listed in table 4 and comprising a solid amorphous form of compound I malate.
- 1 g of compound I malate and 10 g of PVP were dissolved in 187.5 g of water/methanol (70/30 v/v). The solution was spray dried obtaining a product having a bulk density of 0.22 g/ml. Then microcrystalline cellulose (MCC), colloidal silicon dioxide, magnesium stearate and povidone were added and mixed. The mixture having a mean particle size of between 16 and 20 μm was filled into hard gelantine capsules (size 0).
-
TABLE 4 Ingredient Product Function Amount Compound I malate PVP API 138.89 mg MCC Avicel PH 101 filler 60.00 mg Colloidal silicon dioxide Aerosil 200 glidant 2.11 mg Magnesium stearate antisticking 1.00 mg Povidone Kollidon CL binder 48.00 mg Total 250 mg - The XRPD of the spray dried product is shown in
FIG. 3 . The XRPD demonstrates that compound I malate is present in amorphous form. - The dissolution profile of the capsules obtained in this example was compared with the dissolution profile of commercial Sutent® 12.5 mg sunitinib capsules. The dissolution profiles were measured in 900 ml of phosphate puffer pH 3.2 using a spiral capsule sinker at 37° C. and 50 rpm paddle (app.II). The dissolution profiles are shown in
FIG. 4 which demonstrates that the dissolution of the capsules of the present invention is even faster then the dissolution of the commercial sutent capsules.
Claims (28)
1. A pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is present in an amorphous or partially amorphous form.
2. The pharmaceutical composition according to claim 1 , wherein the active pharmaceutical ingredient is present in a spray dried form or lyophilized form.
3. The pharmaceutical composition according to claim 2 , wherein the active pharmaceutical ingredient is present in a spray dried form and the composition is obtained by spray drying the active pharmaceutical ingredient in the presence of at least one excipient selected from the group consisting of polymers based on cellulose, polyvinylpyrrolidone (PVP) and vinylpyrrolidone-vinyl acetate copolymers.
4. The pharmaceutical composition according to claim 1 , wherein the active pharmaceutical ingredient comprises more than 40% of the total weight of the composition.
5. The pharmaceutical composition according to claim 1 , wherein said composition comprises particles having a mean particle size that ranges from 0.3 to 300 μm.
6. The pharmaceutical composition according to claim 1 , wherein said composition has a bulk density that ranges from 0.2 to 0.8 g/ml.
7. The pharmaceutical composition according to claim 1 , wherein said composition has a Hausner ratio that ranges from 1.1 to 1.6.
8. The pharmaceutical composition according to claim 1 , wherein the active pharmaceutical ingredient is a) layered onto particles or pellets comprising one or more pharmaceutically acceptable excipients, b) coated with one or more pharmaceutically acceptable excipients, or c) dispersed or dissolved in a solid melt comprising one or more pharmaceutically acceptable excipients.
9. The pharmaceutical composition according to claim 8 , wherein the active pharmaceutical ingredient comprises more than 40% of the total weight of the composition.
10. The pharmaceutical composition according to claim 8 , wherein said composition comprises particles having a mean particle size that ranges from 1 to 1500 μm.
11. The pharmaceutical composition according to claim 8 , wherein said composition has a bulk density that ranges from 0.3 to 0.85 g/ml.
12. The pharmaceutical composition according to claim 8 , wherein said composition has a Hausner ratio that ranges from 1.05 to 1.45.
13. The pharmaceutical composition according to claim 1 , wherein said composition further comprises one or more pharmaceutically acceptable excipients, such as fillers, binding agents, lubricants, glidants, crystallization inhibitors and disintegrating agents.
14. A process of preparing a pharmaceutical composition according to claim 1 , comprising the steps of:
(a) providing N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient and optionally at least one pharmaceutically acceptable excipient; and
(b) transferring the active pharmaceutical ingredient into its amorphous or partially amorphous form.
15. The process according to claim 14 , wherein in step (b) the active pharmaceutical ingredient is transferred into its amorphous or partially amorphous form by spray drying.
16. The process according to claim 15 , wherein the spray drying is performed in the presence of at least one excipient selected from the group consisting of polymers based on cellulose, plyvinylpyrrolidone (PVP) and vinylpyrrolidone-vinyl acetate copolymers.
17. The process according to claim 14 , wherein in step (b) the active pharmaceutical ingredient is transferred in its amorphous or partially amorphous form by lyophilization.
18. The process according to claim 17 , wherein the active pharmaceutical ingredient is lyophilized in the presence of at least one excipient.
19. The process according to claim 14 , wherein in step (b) the active pharmaceutical ingredient is transferred into its amorphous or partially amorphous form by a) layering the active pharmaceutical ingredient onto particles or pellets comprising one or more pharmaceutically acceptable excipients, by b) coating the active pharmaceutical ingredient with one or more pharmaceutically acceptable excipients, or by c) dispersing or dissolving the active pharmaceutical ingredient in a melt comprising one or more pharmaceutically acceptable excipients.
20. The process according to claim 19 , wherein the active pharmaceutical ingredient is layered onto particles or pellets comprising a mixture of a soluble and an insoluble excipient.
21. The process according to claim 20 , wherein said soluble excipient is mannitol and said insoluble excipient is microcrystalline cellulose.
22. The process according to claim 19 , wherein the active pharmaceutical ingredient is coated with one or more solubility enhancing excipients.
23. The process according to claim 22 , wherein the solubility enhancing excipient is selected from the group consisting of hydroxypropylmethyl cellulose, polyvinylpyrrolidone and mixtures thereof.
24. The process according to claim 19 , wherein the active pharmaceutical ingredient is dispersed or dissolved in a melt of one or more excipients selected from the group consisting of polyethylene glycols, polyvinylpyrrolidone, polyvinyl acetate, cellulose derivatives, sugar alcohols, methacrylates, mixtures of mono-, di- and triglycerides and mixtures of these exipients.
25. A pharmaceutical composition obtained by the process according to claim 14 .
26. A compound comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof in amorphous or partially amorphous form.
27. (canceled)
28. The pharmaceutical composition according to claim 1 , wherein the active pharmaceutical ingredient comprises more than 50% of the total weight of the composition.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08002657A EP2090306A1 (en) | 2008-02-13 | 2008-02-13 | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
EP08002657.8 | 2008-02-13 | ||
EP08008208.4 | 2008-04-29 | ||
EP08008208A EP2113248A1 (en) | 2008-04-29 | 2008-04-29 | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
PCT/EP2009/001034 WO2009100929A1 (en) | 2008-02-13 | 2009-02-13 | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100310668A1 true US20100310668A1 (en) | 2010-12-09 |
Family
ID=40578233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/867,326 Abandoned US20100310668A1 (en) | 2008-02-13 | 2009-02-13 | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100310668A1 (en) |
EP (1) | EP2240174A1 (en) |
CA (1) | CA2713112A1 (en) |
EA (1) | EA201001125A1 (en) |
WO (1) | WO2009100929A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11648201B2 (en) * | 2018-05-02 | 2023-05-16 | Ferring B.V. | Pharmaceutical formulations |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104069076A (en) * | 2013-03-29 | 2014-10-01 | 浙江九洲药业股份有限公司 | Unshaped composition of sunitinib and PVP (Polyvinyl Pyrrolidone) |
WO2014198342A1 (en) * | 2013-06-14 | 2014-12-18 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
CN104367557A (en) * | 2013-08-12 | 2015-02-25 | 浙江九洲药业股份有限公司 | Preparation method of amorphous composition composed of drug active component and PVP |
EP3958845A1 (en) | 2019-04-25 | 2022-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2399358C (en) * | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
HN2003000272A (en) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | FORMULATIONS THAT INCLUDE AN INDOLINONE COMPOUND |
ITRM20030074A1 (en) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | SEMI-SOLID FORMULATIONS WITH IMMEDIATE RELEASE AGREEMENTS |
-
2009
- 2009-02-13 EP EP09711448A patent/EP2240174A1/en not_active Withdrawn
- 2009-02-13 EA EA201001125A patent/EA201001125A1/en unknown
- 2009-02-13 CA CA2713112A patent/CA2713112A1/en not_active Abandoned
- 2009-02-13 WO PCT/EP2009/001034 patent/WO2009100929A1/en active Application Filing
- 2009-02-13 US US12/867,326 patent/US20100310668A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11648201B2 (en) * | 2018-05-02 | 2023-05-16 | Ferring B.V. | Pharmaceutical formulations |
Also Published As
Publication number | Publication date |
---|---|
CA2713112A1 (en) | 2009-08-20 |
EA201001125A1 (en) | 2011-04-29 |
EP2240174A1 (en) | 2010-10-20 |
WO2009100929A1 (en) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6517871B1 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
JP6150777B2 (en) | Solid pharmaceutical compositions and processes for their production | |
US11413295B2 (en) | Oral preparation of obeticholic acid | |
WO2014120982A1 (en) | Solid dispersion formulation of an antiviral compound | |
JP6895779B2 (en) | Azilsartan-containing solid pharmaceutical composition | |
WO2010055119A2 (en) | Pharmaceutical composition comprising pimobendan | |
JP2013518860A (en) | N- (2-chloro-6-methylphenyl) -2-[[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] -5-thiazolecarbosaki Pharmaceutical composition comprising mid | |
TWI790364B (en) | Pharmaceutical composition comprising sodium alkyl sulfate | |
US20100310668A1 (en) | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide | |
US20090162444A1 (en) | Raloxifene composition | |
CA2728852C (en) | Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide | |
WO2021220295A1 (en) | Immediate release pharmaceutical compositions comprising palbociclib | |
WO2017029609A1 (en) | Pharmaceutical composition of alogliptin and metformin | |
EP2158912A1 (en) | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine | |
KR20220077094A (en) | Stability and bioavailability enhanced solid dispersion formulations of Olaparib | |
JP7370126B2 (en) | Pharmaceutical tablets containing erlotinib as the active ingredient | |
EP2113248A1 (en) | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide | |
EP2090306A1 (en) | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | |
JP2022532540A (en) | Pharmaceutical composition containing axitinib | |
EP2255792A1 (en) | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide | |
JP7370124B2 (en) | Pharmaceutical tablets containing erlotinib as the active ingredient | |
KR101956586B1 (en) | Pharmaceutical composition and preparation method thereof | |
US20110263701A1 (en) | Gabapentin enacarbil compositions | |
US20230310327A1 (en) | Pharmaceutical compositions comprising ribociclib | |
US8927011B2 (en) | Method for producing pharmaceutical tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RATIOPHARM GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAETZ, JANA;MUSKULUS, FRANK;SIGNING DATES FROM 20100714 TO 20100728;REEL/FRAME:024828/0926 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |